Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507810 | 0.76 | CYP1A2 (0.44) | TP53KDM4EMAPTCYP1A2CYP3A4 | |
| SCHEMBL14159651 | 0.75 | DAO (0.44) | TP53KDM4EKMT2AALDH1A1PKM | |
| SCHEMBL154592 | 0.74 | KMT2A (0.55) | SLC6A2TP53KDM4EKMT2AMEN1 | |
| SCHEMBL29378766 | 0.74 | KMT2A (0.55) | SLC6A2TP53KDM4EKMT2AMEN1 | |
| SCHEMBL7678437 | 0.74 | SLC6A2 (0.44) | SLC6A2TP53KDM4EKMT2ATSHR | |
| SCHEMBL8598225 | 0.74 | NOS2 (0.43) | TP53KDM4EKMT2ATSHRNOS2 | |
| SCHEMBL3008864 | 0.73 | DAO (0.52) | SLC6A2TP53KDM4EKMT2ATSHR | |
| SCHEMBL3973543 | 0.73 | SLC6A2 (0.43) | SLC6A2TP53KDM4EKMT2ATSHR | |
| SCHEMBL18525155 | 0.73 | SLC6A2 (0.43) | SLC6A2TP53KDM4EKMT2ATSHR | |
| SCHEMBL6114342 | 0.73 | SLC6A2 (0.43) | SLC6A2TP53KDM4EKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | claimed |
| WO-2025056724-A1 | IMINOAMIDE-TYPE COMPOUNDS AS LIGANDS FOR COPPER-CATALYZED COUPLING REACTIONS OF (HETERO)ARYL HALIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025056725-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED PHENOLS VIA COPPER-CATALYZED COUPLING REACTIONS OF HALOGENATED ARYL-HALIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-20 | — | — | WO | disclosed |
| US-20230276696-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2023-08-31 | — | — | US | disclosed |
| US-11716898-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-01 | — | — | US | disclosed |
| US-11678565-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| US-11114626-B2 | Metal compounds, methods, and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200295276-A1 | Organic Electroluminescent Materials and Devices | UNIVERSAL DISPLAY CORP (US) | 2020-09-17 | — | — | US | disclosed |
| WO-1997004777-A1 | USE OFF UNSUBSTITUTED AND SUBSTITUTED N-(PYRROL-1-YL)PYRIDINAMINES AS ANTICONVULSANT AGENTS | HOECHST MARION ROUSSEL, INC. (US) | 1997-02-13 | — | — | WO | disclosed |
| WO-1996026183-A1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | NOVARTIS AG (CH) | 1996-08-29 | — | — | WO | disclosed |
| EP-0635269-A1 | Use of N-(Pyridinyl)-1H-Indol-1-Amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5356910-A | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-10-18 | — | — | US | disclosed |
| US-5039811-A | Analgesics, antidepressants, memory activators; condensation, reduction | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-08-13 | — | — | US | disclosed |
| EP-0397040-A2 | N-heteroaryl-4-quinolinamines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-11-14 | — | — | EP | disclosed |
| US-4970218-A | ANALGESIC, ANTIDEPRESSANT, MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-11-13 | — | — | US | disclosed |
| US-4916135-A | ANALGESICS, ALZHEIMER*S | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1990-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11716898-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, JUND | SLC6A2 1328/4885TP53 3742/4885KDM4E 2637/4885 |
| US-11678565-B2 | Organic electroluminescent materials and devices | OCIAD1, OCIAD2, OPRD1 | SLC6A2 3013/4885TP53 3538/4885KDM4E 3475/4885 |
| US-11114626-B2 | Metal compounds, methods, and uses thereof | SOD1, SOD3, AOX1 | SLC6A2 1678/4885TP53 3013/4885KDM4E 4380/4885 |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | SLC6A2 4643/4885TP53 1426/4885KDM4E 2494/4885 |
| US-20200295276-A1 | Organic Electroluminescent Materials and Devices | OCIAD2, OCIAD1, JUND | SLC6A2 1328/4885TP53 3742/4885KDM4E 2637/4885 |
| US-20230276696-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, PORCN | SLC6A2 2379/4885TP53 3915/4885KDM4E 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.